$7.98
1.24% today
Nasdaq, Apr 01, 07:18 pm CET
ISIN
SG9999014716
Symbol
WVE
Sector
Industry

Wave Life Sciences Ltd. Stock price

$8.08
-2.49 23.56% 1M
-0.12 1.46% 6M
-4.29 34.68% YTD
+1.77 28.05% 1Y
+6.08 304.00% 3Y
-1.29 13.77% 5Y
-7.92 49.50% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.54 6.26%
ISIN
SG9999014716
Symbol
WVE
Sector
Industry

Key metrics

Market capitalization $1.24b
Enterprise Value $971.36m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.97
P/S ratio (TTM) P/S ratio 11.45
P/B ratio (TTM) P/B ratio 5.90
Revenue growth (TTM) Revenue growth -4.42%
Revenue (TTM) Revenue $108.30m
EBIT (operating result TTM) EBIT $-110.40m
Free Cash Flow (TTM) Free Cash Flow $-152.45m
Cash position $302.08m
EPS (TTM) EPS $-0.79
P/E forward negative
P/S forward 17.79
EV/Sales forward 13.93
Short interest 9.32%
Show more

Is Wave Life Sciences Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Wave Life Sciences Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Wave Life Sciences Ltd. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Wave Life Sciences Ltd. forecast:

Buy
91%
Hold
9%

Financial data from Wave Life Sciences Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
108 108
4% 4%
100%
- Direct Costs 8.66 8.66
6% 6%
8%
100 100
4% 4%
92%
- Selling and Administrative Expenses 42 42
27% 27%
39%
- Research and Development Expense 160 160
23% 23%
147%
-102 -102
73% 73%
-94%
- Depreciation and Amortization 8.66 8.66
6% 6%
8%
EBIT (Operating Income) EBIT -110 -110
62% 62%
-102%
Net Profit -97 -97
68% 68%
-90%

In millions USD.

Don't miss a Thing! We will send you all news about Wave Life Sciences Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Wave Life Sciences Ltd. Stock News

Positive
Seeking Alpha
5 days ago
Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved in the phase 2 FORWARD-53 study, using WVE-N531 for the treatment of patients with DMD amenable to exon 53 skipping; an average dystrophin expression of 7.8% was achieved. The Duchenne Muscular Dyst...
Neutral
GlobeNewsWire
6 days ago
Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA
Neutral
Seeking Alpha
28 days ago
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Kate Rausch - VP, IR & Corporate Affairs Paul Bolno - President & CEO Erik Ingelsson - Chief Scientific Officer Kyle Moran - Chief Financial Officer Conference Call Participants Ron Feiner - JPMorgan Salim Syed - Mizuho Joon Lee - Truist Securities Joe Schwartz - Leerink Partners...
More Wave Life Sciences Ltd. News

Company Profile

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Head office Singapore
CEO Paul Bolno
Employees 288
Founded 2012
Website www.wavelifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today